Logo-bi
Bioimpacts. 2017;7(4): 209-217. doi: 10.15171/bi.2017.25
PMID: 29435428        PMCID: PMC5801532

Methodology

Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis

Farhad Shokraneh 1 * ORCID, Clive Elliott Adams 1 ORCID

Cited by CrossRef: 86

1- Shokraneh F, Adams C. Study-based registers reduce waste in systematic reviewing: discussion and case report. Syst Rev. 2019;8(1) [Crossref]
2- Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. 2018;2018(1) [Crossref]
3- Wu H, Siafis S, Wang D, Burschinski A, Schneider-Thoma J, Priller J, Davis J, Leucht S. Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis. European Neuropsychopharmacology. 2023;72:40 [Crossref]
4- Hahn M, Agarwal S, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G. Pharmacological interventions for reduction of weight gain in people with schizophrenia. 2019; [Crossref]
5- Li Y, Du C, Jiaxiang N, Liqiang Y, Qi F. Olanzapine versus placebo for people with schizophrenia. 2019; [Crossref]
6- Agarwal S, Stogios N, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. Pharmacological interventions for prevention of weight gain in people with schizophrenia. 2022;2023(1) [Crossref]
7- Dib J, Adams C. Identification of surveys in major biomedical bibliographic databases. Journal of Clinical Epidemiology. 2021;133:170 [Crossref]
8- Guaiana G, Abbatecola M, Aali G, Tarantino F, Ebuenyi I, Lucarini V, Li W, Zhang C, Pinto A. Cognitive behavioural therapy (group) for schizophrenia. 2022;2022(7) [Crossref]
9- Shokraneh F, Adams C. Cochrane Schizophrenia Group’s Study-Based Register of Randomized Controlled Trials: Development and Content Analysis. 2020;1(1) [Crossref]
10- Takeuchi H, Shimomura Y, Kikuchi Y, Nomura N, Hird E, Wu H, Agid O, Leucht S. Placebo versus no treatment for people with schizophrenia. 2023;2023(1) [Crossref]
11- Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. 2018;2018(3) [Crossref]
12- Shokraneh F. Reducing waste and increasing value through embedded replicability and reproducibility in systematic review process and automation. Journal of Clinical Epidemiology. 2019;112:98 [Crossref]
13- Schmidt L, Phelps E, Friedel J, Shokraneh F. Acetylsalicylic acid (aspirin) for schizophrenia. 2019;2019(8) [Crossref]
14- Ceraso A, LIN J, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, Heres S, Kissling W, Davis J, Leucht S. Maintenance treatment with antipsychotic drugs for schizophrenia. 2020;2020(8) [Crossref]
15- Zaman H, Gibson R, Walcott G. Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. 2019;2019(8) [Crossref]
16- Schneider-Thoma J, Kapfhammer A, Wang D, Bighelli I, Siafis S, Wu H, Hansen W, Davis J, Salanti G, Leucht S. Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials. Syst Rev. 2021;10(1) [Crossref]
17- Iqbal Y, Connell C, Worthington M, Elrafei H, Mulvaney C, Kaewchaluay C. Quetiapine dose for people with schizophrenia. 2019; [Crossref]
18- Chien W, Ma C, Bressington D, Suen L. Family-based interventions versus standard care for people with schizophrenia. 2020; [Crossref]
19- Valera-Calero J, Fernández-de-las-Peñas C, Navarro-Santana M, Plaza-Manzano G. Efficacy of Dry Needling and Acupuncture in Patients with Fibromyalgia: A Systematic Review and Meta-Analysis. IJERPH. 2022;19(16):9904 [Crossref]
20- Bighelli I, Çıray O, Salahuddin N, Leucht S. Cognitive behavioural therapy without medication for schizophrenia. 2024;2024(2) [Crossref]
21- Shokraneh F. Reproducibility and replicability of systematic reviews. WJMA. 2019;7(3):66 [Crossref]
22- Roberts M, Lloyd J, Välimäki M, Ho G, Freemantle M, Békefi A. Video games for people with schizophrenia. 2021;2021(2) [Crossref]
23- Välimäki M, Varpula J, Lantta T. Post-incident debriefing for people with schizophrenia after coercive measures. 2023;2023(4) [Crossref]
24- Morris K, Reid G, Spencer S. Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia. 2018;2018(10) [Crossref]
25- Puntis S, Minichino A, De Crescenzo F, Cipriani A, Lennox B. Specialised early intervention teams for first episode psychosis. 2019; [Crossref]
26- Ibragimov K, Keane G, Carreño Glaría C, Cheng J, Llosa A. Haloperidol versus olanzapine for people with schizophrenia. 2019; [Crossref]
27- Reilly S, Hobson-Merrett C, Gibbons B, Jones B, Richards D, Plappert H, Gibson J, Green M, Gask L, Huxley P, Druss B, Planner C. Collaborative care approaches for people with severe mental illness. 2024;2024(5) [Crossref]
28- Sender D, Clark J, Hoffmann T. Analysis of articles directly related to randomized trials finds poor protocol availability and inconsistent linking of articles. Journal of Clinical Epidemiology. 2020;124:69 [Crossref]
29- Castiello-de Obeso S, Aguayo Mendoza M, Ortiz-Orendain J, Itzaman I, Landa-Ramírez E, Carmona J, Murphy R. Computer-based Cognitive Remediation Therapy plus standard care versus standard care for people with schizophrenia or related disorders. 2020; [Crossref]
30- Buitrago-Garcia D, Sánchez Vanegas G, Sánchez Correa P, Baracaldo S, Gallego Gallego S, Baandrup L. Cannabidiol for people with schizophrenia. 2022;2022(11) [Crossref]
31- Puntis S, Minichino A, De Crescenzo F, Harrison R, Cipriani A, Lennox B. Specialised early intervention teams for recent-onset psychosis. 2020;2021(2) [Crossref]
32- Siafis S, Schneider-Thoma J, Hamza T, Bighelli I, Dong S, Hansen W, Davis J, Salanti G, Leucht S. Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. BMJ Open. 2023;13(2):e064504 [Crossref]
33- Turkmani K, Marwa M, Ahmad B, Ahmad T, Alrstom A, Essali A. Clozapine (generic versus branded) for people with schizophrenia. 2019; [Crossref]
34- Ortiz-Orendain J, Covarrubias-Castillo S, Vazquez-Alvarez A, Castiello-de Obeso S, Arias Quiñones G, Seegers M, Colunga-Lozano L. Modafinil for people with schizophrenia or related disorders. 2019; [Crossref]
35- Hunt G, Siegfried N, Morley K, Brooke-Sumner C, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. 2019;2019(12) [Crossref]
36- Bighelli I, Samara M, Rodolico A, Hansen W, Leucht S. Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. 2021; [Crossref]
37- Bighelli I, Rodolico A, Siafis S, Samara M, Hansen W, Salomone S, Aguglia E, Cutrufelli P, Bauer I, Baeckers L, Leucht S. Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. 2022;2022(8) [Crossref]
38- Tsujimoto Y, Nakamura Y, Banno M, Kohmura K, Tsujimoto H, Kataoka Y. Humour-based interventions for people with schizophrenia. 2021;2021(10) [Crossref]
39- Kotecha A, Upthegrove R. Celecoxib plus standard care for people with schizophrenia. 2018; [Crossref]
40- Guaiana G, Lucarini V, Ebuenyi I, Abbatecola M, Tarantino F, Santoro A, Ghiandi G, Cappiello A, Pinto A. Meta-cognitive training for schizophrenia. 2023;2023(3) [Crossref]
41- Roson Rodriguez P, Chen X, Arancibia M, Garegnani L, Escobar Liquitay C, Mohammad H, Franco J. Transitional discharge interventions for people with schizophrenia. 2024;2024(8) [Crossref]
42- Roberts M, Shokraneh F, Sun Y, Groom M, Adams C. Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies. Evid Based Mental Health. 2021;24(2):62 [Crossref]
43- Ibragimov K, Keane G, Carreño Glaría C, Cheng J, Llosa A. Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders. 2024;2024(7) [Crossref]
44- Datta S, Daruvala R, Kumar A. Psychological interventions for psychosis in adolescents. 2020; [Crossref]
45- Storman D, Koperny M, Styczeñ K, Datka W, Jaeschke R. Lurasidone versus typical antipsychotics for schizophrenia. 2025;2025(1) [Crossref]
46- Eslami Shahrbabaki M, Dehnavieh R, Vali L, Sharafkhani R. Chlorpromazine versus piperacetazine for schizophrenia. 2018;2018(10) [Crossref]
47- Cuesta-Lozano D, Lopez-Alcalde J, Castro Molina F, García Sastre M, Maravilla Herrera P, Muriel A, Asenjo-Esteve Á, Alvarez-Diaz N, Monge Martín D, Carralero-Montero A. Psychoeducation for the parents of people with severe mental illness. 2022;2022(6) [Crossref]
48- Ma C, Chien W, Chan S, Wong C. Behavioural family interventions versus structural family interventions for people with schizophrenia. 2022;2022(8) [Crossref]
49- Agarwal S, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. Pharmacological interventions for prevention of weight gain in people with schizophrenia. 2019; [Crossref]
50- Asenjo-Lobos C, Cortés-Jofré M, Fonseca C, Leucht S, Madrid E, Bonfill Cosp X. Clozapine versus risperidone for people with schizophrenia. 2018; [Crossref]
51- Ostinelli E, D’Agostino A, Shokraneh F, Salanti G, Furukawa T. Acute interventions for aggression and agitation in psychosis: study protocol for a systematic review and network meta-analysis. BMJ Open. 2019;9(10):e032726 [Crossref]
52- Radley J, Grant C, Barlow J, Johns L. Parenting interventions for people with schizophrenia or related serious mental illness. 2021;2021(10) [Crossref]
53- Perry L, Ramson D, Stricklin S. Mirtazapine adjunct for people with schizophrenia. 2018;2018(5) [Crossref]
54- Roson Rodriguez P, Franco J, Garegnani L, Arancibia M, Escobar Liquitay C, Mohammad H. Transitional discharge interventions for people with serious mental illness. 2019; [Crossref]
55- Huang M, Gibson R, Jayaram M, Caroff S. Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms. 2022;2022(7) [Crossref]
56- Radley J, Grant C, Barlow J, Johns L. Parenting interventions for people with schizophrenia or related serious mental illness. 2020; [Crossref]
57- Välimäki M, Lantta T, Kontio R. Risk assessment for aggressive behaviour in schizophrenia. 2024;2024(5) [Crossref]
58- Li J, Shen J, Li B, Wu J. Tai Chi plus standard care versus other exercise plus standard care for people with schizophrenia or related disorders. 2020; [Crossref]
59- Asenjo-Lobos C, Fonseca C, Leucht S, Arancibia M, Cortés-Jofré M. Clozapine versus olanzapine for people with schizophrenia. 2018; [Crossref]
60- Ostinelli E, Zangani C, Solmi M. Clozapine for persistent aggressive behaviour or agitation in people with schizophrenia. 2019; [Crossref]
61- Roson Rodriguez P, Chen X, Arancibia M, Madrid E, Shokraneh F, Adams C, Franco J. Mental Health Services for Serious Mental Illness: Scoping Review of Randomised Controlled Trials. Nursing Open. 2025;12(1) [Crossref]
62- Aali G, Kariotis T, Shokraneh F. Avatar Therapy for people with schizophrenia or related disorders. 2020;2020(5) [Crossref]
63- Puntis S, Minichino A, De Crescenzo F, Harrison R, Cipriani A, Lennox B. Specialised early intervention teams (extended time) for recent-onset psychosis. 2020;2021(2) [Crossref]
64- Shokraneh F, Adams C. Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: A study‐based analysis. Health Info Libraries J. 2023;40(2):201 [Crossref]
65- Bighelli I, Çıray O, Leucht S. Cognitive behavioural therapy without medication for schizophrenia. 2022;2022(7) [Crossref]
66- Rodolico A, Siafis S, Bighelli I, Samara M, Hansen W, Salomone S, Aguglia E, Cutrufelli P, Bauer I, Baeckers L, Leucht S. Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. 2022;2022(11) [Crossref]
67- Assalman I, Ahmed A, Alhajjar R, Bewley A, Taylor R. Treatments for primary delusional infestation. 2019; [Crossref]
68- Wu H, Burschinski A, Schneider-Thoma J, Leucht S, Siafis S. Antipsychotics for antipsychotic-naïve people with psychosis. 2024;2024(2) [Crossref]
69- Asenjo-Lobos C, Fonseca C, Leucht S, Garcia-Ribera C, Cortés-Jofré M. Clozapine versus quetiapine for people with schizophrenia. 2018; [Crossref]
70- Gao Y, Zhu Y, Zeng J, Ye J, Zheng Y, Wei Y, Xu L, Raballo A, Li C, Wang J, Zhang T. Nutritional interventions for early psychosis: a systematic review and network meta-analysis. 2024;2024(1) [Crossref]
71- Huang M, Gibson R, Moberg P, Caroff S. Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms. 2018; [Crossref]
72- Jones C, Hacker D, Xia J, Meaden A, Irving C, Zhao S, Chen J, Shi C. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. 2018;2018(12) [Crossref]
73- Shokraneh F, Adams C. A simple formula for enumerating comparisons in trials and network meta-analysis. F1000Res. 2019;8:38 [Crossref]
74- Kimhy D, Ospina L, Messer S, Sharma V, Datta S, Stroup T. Psychosocial telemedicine interventions for schizophrenia. 2024;2024(2) [Crossref]
75- Puntis S, Minichino A, De Crescenzo F, Cipriani A, Lennox B. Specialised early intervention teams (extended time) for first episode psychosis. 2019; [Crossref]
76- Kohmura K, Banno M, Tsujimoto H, Tsujimoto Y, Kataoka Y. Humour-based interventions for people with schizophrenia. 2019; [Crossref]
77- Broderick J, Vancampfort D. Yoga as part of a package of care versus non-standard care for schizophrenia. 2019;2019(8) [Crossref]
78- Wu H, Jiang J, Cao X, Wang J, Li C. Magnetic seizure therapy for people with schizophrenia. 2023;2023(6) [Crossref]
79- Latifeh Y, Mohsen M, Mohamad S, Nassif T. Olanzapine dose for people with schizophrenia. 2019; [Crossref]
80- Bighelli I, Corcoran C, Umama-Agada E, Leucht S. Cognitive behavioural therapy plus standard care for first episode psychosis. 2022;2022(5) [Crossref]
81- Yap M, Debenham L, Kew T, Chatterjee S, Allotey J, Stallings E, Coomar D, Lee S, Qiu X, Yuan M, Clavé Llavall A, Dixit A, Zhou D, Balaji R, van Wely M, Kostova E, van Leeuwen E, Mofenson L, Kunst H, Khalil A, Tiberi S, Thomas J, Brizuela V, Broutet N, Kara E, Kim C, Thorson A, Rayco-Solon P, Pardo-Hernandez H, Oladapo O, Zamora J, Bonet M, Thangaratinam S. Clinical manifestations, prevalence, risk factors, outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and postpartum: a living systematic review protocol. BMJ Open. 2020;10(12):e041868 [Crossref]
82- Mayer S, Corcoran C, Kennedy L, Leucht S, Bighelli I. Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis. 2024;2024(3) [Crossref]
83- Shokraneh F, Adams C. A simple formula for enumerating comparisons in trials and network meta-analysis. F1000Res. 2019;8:38 [Crossref]
84- Essali A, Turkmani K, Aboudamaah S, AbouDamaah A, Diaa Aldeen M, Marwa M, AlMounayer N. Haloperidol discontinuation for people with schizophrenia. 2019;2019(4) [Crossref]
85- Martínez-Vélez N, Escamilla Orozco R, Flores Medina Y, Saracco-Alvarez R, Rosel Vales M, Aguilar-Salas I, Sánchez-Hernández G. Aripiprazole versus brexpiprazole for people with schizophrenia. 2023;2023(2) [Crossref]
86- Bighelli I, Samara M, Rodolico A, Hansen W, Leucht S. Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. 2021; [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of COPE
Follower of ICMJE
Permission: Creative Commons